Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital
Authors
Narine, N.Wallace, A. J.
Dore, J.
O'Leary-Jackson, S.
Al-Najjar, H.
Bailey, S.
Khan, K. A.
Teng, B.
Qasim, M.
Shelton, D.
Holbrook, M.
Abbasi, S.
Carter, M.
Irion, L.
Al-Habba, S.
Lindsay, Colin R
Blackhall, Fiona H
Rana, D. N.
Affiliation
Manchester University NHS Foundation Trust. The Christie NHS Foundation Trust.Issue Date
2021
Metadata
Show full item recordAbstract
Objective: This is a prospective evaluation of ROS1 analysis by IHC against FISH on cytology and small biopsy samples in a routine diagnostic setting and demonstrates both technical and clinical validation. Methods: From 1st March to 31st December 2019, cytology cell blocks and small biopsy samples from a selected cohort of NSCLC patients were concurrently tested for ROS1 gene rearrangement by Vysis 6q22 Break Apart FISH probe and IHC using Cell Signalling D4D6 antibody. Mismatch cases were tested by an RNA fusion NGS panel. Results: In a prospective population of 95 cases, 91 were negative and 2 were positive by both FISH and IHC. Both dual positive cases were female never smokers and benefited from TKI treatment. Another 2 cases were positive by FISH but negative by IHC and repeat by NGS showed one to be negative but one failed. Turnaround time for IHC was 0 to 8 days from request to authorisation whilst that of FISH was 9 to 42 days at a cost of £51 and £159 respectively. Conclusion: IHC to assess for the protein product of ROS1 gene rearrangement on cytology cell blocks and small biopsy samples in a routine setting is a promising screening method to assess eligibility for TKI treatment with positive and indeterminate cases confirmed by FISH or NGS as it has good NPV, faster turnaround time and is cost effective with proven technical and clinical validationCitation
Narine N, Wallace A, Dore J, O’Leary-Jackson S, Al Najjar H, Bailey S, et al. Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. Cytopathology. 2021 Jun 15.Journal
CytopathologyDOI
10.1111/cyt.12994PubMed ID
34033159Additional Links
https://dx.doi.org/10.1111/cyt.12994Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/cyt.12994
Scopus Count
Collections
Related articles
- Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
- Authors: Vlajnic T, Savic S, Barascud A, Baschiera B, Bihl M, Grilli B, Herzog M, Rebetez J, Bubendorf L
- Issue date: 2018 Jun
- Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
- Authors: Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC
- Issue date: 2017 Sep
- Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
- Authors: Wu J, Lin Y, He X, Yang H, He P, Fu X, Li G, Gu X
- Issue date: 2016 Aug 4
- ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
- Authors: Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB
- Issue date: 2022 Apr
- On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
- Authors: Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A
- Issue date: 2014 Feb